CHAMPIONS ONCOLOGY, INC.
CSBR · Biological Products, (No Diagnostic Substances) · 13.9M shares · +3%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$484K (gross $634K, SBC $1M)
Grade
C64Oncology research-services company (TumorGraft) — profitable with positive FCF, but thin liquidity.
Strengths
- Profitable with positive FCF — operating margin 8% (86th), FCF $7M (88th), ROA 15% (93rd)
- Growth — revenue +14%
Risks
- Thin liquidity — current ratio 0.9 (18th)
- Earnings comp — net income -165%
- Customer concentration (pharma R&D budgets) — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Weak liquidityCurrent ratio 0.94 (<1)
- Customer concentration~25% of revenue from one customer/distributor — Results of Operations The following table summarizes our operating results for the periods presented below (dollars in thousands): For the Years Ended April 30, 2025 % of Revenue 2024 % of Rev
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Notable holderHeld by 2 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
50.1%
Operating margin
8.0%
Net margin
8.3%
Return on equity
124.6%
Return on assets
14.5%
Revenue growth (QoQ)
10.1%
Current ratio
0.9×
Free cash flow
$7M
EBITDA
$6M
Tangible book value
$3M
Stock comp / revenue
1.1%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-10-30 | ACKERMAN JOEL | Option exercise | 94K | $2.10 |
| 2025-03-25 | Breitfeld Philip P. | Other | 4.2K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-03-30 | 2026-03-24 | 0001628280-26-021941 ↗ |
| 8-K | 2026-03-12 | 2026-03-12 | 0001628280-26-017259 ↗ |
| 10-Q | 2026-03-12 | 2026-01-31 | 0001628280-26-017345 ↗ |
| 10-Q | 2025-12-15 | 2025-10-31 | 0001628280-25-057082 ↗ |
| 8-K | 2025-12-15 | 2025-12-15 | 0001628280-25-057020 ↗ |
| 8-K | 2025-10-16 | 2025-10-16 | 0001628280-25-045241 ↗ |
| 10-Q | 2025-09-15 | 2025-07-31 | 0000771856-25-000023 ↗ |
| 8-K | 2025-09-15 | 2025-09-15 | 0000771856-25-000022 ↗ |
| 10-K | 2025-07-23 | 2025-04-30 | 0001628280-25-035765 ↗ |
| 8-K | 2025-07-23 | 2025-07-23 | 0001628280-25-035727 ↗ |
| 8-K | 2025-07-21 | 2025-07-21 | 0001628280-25-035424 ↗ |
| 10-Q | 2025-03-17 | 2025-01-31 | 0001628280-25-012941 ↗ |